Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Quickcomparison

Dose Range Human Growth Hormone (HGH) 1–4 IU IGF-1 LR3 20–100 mcg Frequency Once daily Administration Subcutaneous injection Cycle Length 12+ weeks 4-6 weeks Onset Speed Gradual (3-4 weeks) Rapid (hours to days) Evidence Level Strong human trials (Phase 3 or F

This comparison does not assign a generated winner or score.

  • Dose Range
  • Human Growth Hormone (HGH)
  • 1–4 IU
  • IGF-1 LR3
  • 20–100 mcg
  • Frequency
  • Once daily
  • Administration
  • Subcutaneous injection
  • Cycle Length
  • 12+ weeks
  • 4-6 weeks
  • Onset Speed
  • Gradual (3-4 weeks)
  • Rapid (hours to days)
  • Evidence Level
  • Strong human trials (Phase 3 or FDA approved)
  • Strong preclinical (extensive animal studies)
  • Efficacy
More references

Related material

Comparison

IGF-1 LR3 versus IGF-1 DES

Another common IGF-1 variant, IGF-1 DES (Des 1-3), takes the opposite approach to modification. Instead of adding amino acids, DES removes the first three from the N-terminus, cre…

View details →